
Bleonix15 unit/vi
Beacon Pharmaceuticals PLC
Bleomycin Sulfate is an antitumor antibiotic used, usually as part of combination chemotherapy regimens and more.
Bleomycin Sulfate is an antitumor antibiotic used, usually as part of combination chemotherapy regimens, for the following established indications:
Bleomycin Sulfate is administered only under the supervision of a qualified oncologist as part of a defined chemotherapy protocol; it is not used as monotherapy for most solid tumor indications and requires cumulative-dose monitoring.
Dosage of Bleomycin Sulfate is expressed in units and must be individualized by the treating oncologist based on indication, combination regimen, and cumulative lifetime dose. Doses are typically calculated per body surface area or per kilogram body weight.
| Indication | Typical adult dosing of Bleomycin Sulfate |
|---|---|
| Hodgkin lymphoma / non-Hodgkin lymphoma | 0.25–0.5 units/kg (10–20 units/m²) IV, IM, or SC, once or twice weekly, as part of combination chemotherapy; after ~50% response, a maintenance dose of 1 unit daily or 5 units weekly (IM/IV) may be used |
| Squamous cell carcinoma (head & neck, skin, cervix, vulva) | 0.25–0.5 units/kg (10–20 units/m²) IV, IM, or SC, once or twice weekly |
| Testicular carcinoma | 0.25–0.5 units/kg (10–20 units/m²) IV, IM, or SC, once or twice weekly, in combination regimens |
| Malignant pleural effusion (pleurodesis) | A single intrapleural instillation of 60 units, diluted in 50–100 mL of 0.9% sodium chloride, after drainage of the effusion |
Test dose: Because lymphoma patients are at increased risk of an acute idiosyncratic (anaphylactoid) reaction to Bleomycin Sulfate, a test dose of 1–2 units is often given before the first one or two treatments, with the patient observed for hypotension, wheezing, fever, or confusion.
Cumulative dose limit: The risk of pulmonary fibrosis with Bleomycin Sulfate rises sharply once the total cumulative dose exceeds approximately 400 units; treatment beyond this threshold is generally avoided unless the anticipated benefit clearly outweighs the risk.
Renal impairment: Since Bleomycin Sulfate is cleared primarily by the kidneys, a substantial dose reduction is required in patients with reduced creatinine clearance; the exact adjustment should follow institutional oncology protocols.
This medicine must only be prepared and administered by trained healthcare professionals in a facility equipped to manage chemotherapy-related emergencies; see Precautions and Warnings.
Common and important adverse effects associated with Bleomycin Sulfate include:
Bleomycin Sulfate is contraindicated in patients with a known history of severe hypersensitivity to bleomycin or any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.